Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

5.150 -0.060 (-1.15%)
Official Closing Price Updated: 7:59 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aprea Therapeutics Inc

Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
From GlobeNewswire News Releases
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
From GlobeNewswire News Releases
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
From GlobeNewswire News Releases
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
From GlobeNewswire News Releases
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
From GlobeNewswire News Releases
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
From GlobeNewswire News Releases
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
From GlobeNewswire News Releases
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
From GlobeNewswire News Releases
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
From GlobeNewswire News Releases
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
From GlobeNewswire News Releases
Aprea Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
From GlobeNewswire News Releases
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
From GlobeNewswire News Releases
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
From GlobeNewswire News Releases
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia a
From GlobeNewswire News Releases
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
From GlobeNewswire News Releases
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
From GlobeNewswire News Releases
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
From GlobeNewswire News Releases
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Aprea Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
From GlobeNewswire News Releases
Aprea Therapeutics Launches New Corporate Website - www.aprea.com
From GlobeNewswire News Releases
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
From GlobeNewswire News Releases
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
From GlobeNewswire News Releases
Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
From GlobeNewswire News Releases
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presen
From GlobeNewswire News Releases
Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
From GlobeNewswire News Releases
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML
From GlobeNewswire News Releases
Aprea Therapeutics Reports Third Quarter 2019 Financial Results
From GlobeNewswire News Releases
Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
Company to host Clinical Update meeting and webcast on Monday, December 9 at 12:00 PM ET 
From GlobeNewswire News Releases
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.